He mentioned, "There hasn't been a notable opposition from our members in challenging these items, possibly because they don't meet the criteria under 503A." According to Section 503A of the Food, Drug & Cosmetic Act, an eligible bulk drug substance for compounding must be a component of an FDA-approved drug, must have a USP or NF monograph, or must appear on the FDAs 503A Bulks List or Interim Bulks List Category 1
Treating severe pernicious anemia with vitamin B12 can cause low potassium and high platelet levels
Over five years, the researchers found: Osteoporosis developed in about 4.1 percent of GLP-1 users, compared with 3.2 percent of nonusers a roughly 29 percent higher relative risk
Although use of these products is generally considered safe and well-tolerated, further research is needed to assess any long-term effects
READY TO FEEL BETTER
For example, some patients cycle off of their therapy once theyve reached a milestone